Type 2 Diabetes Mellitus Patients' Characteristics and Management by General Practitioners and Endocrinologists
A Non-Interventional Study on Type 2 Diabetes Mellitus Patient's Characteristics and Management by General Practitioners and Endocrinologists in the Russian Population (THESEUS)
This is a multi-centre observational, ambispective study, which will retrospectively and prospectively collect clinical variables and socio-demographic data from medical records of patients with type 2 diabetes mellitus (T2DM) initiated with dapagliflozin by general practitioners (GPs) and endocrinologists in real-life setting. It is anticipated that patient recruitment will last 8 months (from Q3 2017 to Q1 2018) and each patient will be followed during the second visit 6±3 months later after the first visit. There are 2 time points:
- Baseline data: baseline data are defined as data available within 3 months prior to the first dose of dapagliflozin. In case of presence of multiple data values within baseline period the most recent pre-dose value will be selected
- Follow-up data: any post-baseline data will be considered as follow-up but the primary analysis will be focused on data available at 6±3 months after the first visit. In case of discontinuation dapagliflozin, data will be collected at routine visit within 3-month time frame after the last dose
연구 개요
상태
정황
상세 설명
Study design:
This is a multi-centre observational, ambispective study, which will retrospectively and prospectively collect clinical variables and socio-demographic data from medical records of patients with T2DM initiated with dapagliflozin by GPs and endocrinologists in real-life setting.
Only patients, who provide written consent to participate in the study will be enrolled into this study. All patients will be unique with no overlap between endocrinologists and GPs. All consecutive patients managed by GPs or endocrinologists who meet inclusion criteria will be included. All GPs and endocrinologists, who manage T2DM on sites, will be participating investigators.
Patients will undergo clinical assessment and receive the standard medical care as usual determined by the treating doctor based on their clinical judgement and national guidelines. Patients will not receive experimental treatment as a consequence of their participation in the observational study.
It is anticipated that patient recruitment will last for 8 months (from Q3 2017 to Q1 2018) and each patient will be followed during the second visit 6±3 months later after the first visit.
There are 2 time points:
- Baseline data: baseline data are defined as data available within 3 months prior to the first dose of dapagliflozin. In case of presence of multiple data values within baseline period the most recent pre-dose value will be selected
- Follow-up data: any post-baseline data will be considered as follow-up but the primary analysis will be focused on data available at 6±3 months after the first visit. In case of discontinuation dapagliflozin, data will be collected at routine visit within 3-month time frame after the last dose.
Data Source(s):
Baseline data will be collected during Visit 1 from the T2DM patient medical records, including disease history of patient, and during follow-up data during Visit 2 (after 6±3 months from Visit 1).
Study Population:
It is planned to include 900 male and female T2DM outpatients 18 years and older, who were managed by GPs or endocrinologists in 45 outpatient sites.
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
-
Belgorod Region, Shebekino, 러시아 연방, D1690R00037
- Research Site
-
Belgorod Region, Volokonovsky R-n, P. Volokonovka, 러시아 연방, D1690R00037
- Research Site
-
Gis-Khrustalny, 러시아 연방, D1690R00037
- Research Site
-
Izhevsk, 러시아 연방, D1690R00037
- Research Site
-
Kazan, 러시아 연방, D1690R00037
- Research Site
-
Lipetsk, 러시아 연방, D1690R00037
- Research Site
-
N. Novgorod, 러시아 연방, D1690R00037
- Research Site
-
N. Novgorod Region, 러시아 연방, D1690R00037
- Research Site
-
Novomoskovsk, 러시아 연방, D1690R00037
- Research Site
-
Novosibirsk, 러시아 연방, D1690R00037
- Research Site
-
Perm, 러시아 연방, D1690R00037
- Research Site
-
Ryazan, 러시아 연방, D1690R00037
- Research Site
-
Samara, 러시아 연방, D1690R00037
- Research Site
-
St-petersburg, 러시아 연방, D1690R00037
- Research Site
-
Tambov Region, 러시아 연방, D1690R00037
- Research Site
-
Volzhsk, 러시아 연방, D1690R00037
- Research Site
-
Voronezh, 러시아 연방, D1690R00037
- Research Site
-
Voronezh Region, Novovoronezh, 러시아 연방, D1690R00037
- Research Site
-
Yaroslavl, 러시아 연방, D1690R00037
- Research Site
-
Yoshkar-Ola, 러시아 연방, D1690R00037
- Research Site
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- Age 18 and older;
- Established diagnosis of T2DM (ICD-10 code E11.2-E11.9)
- The current treatment with dapagliflozin prescribed at least 1 month before the FSI;
- Written voluntary informed consent has been provided
- Management in outpatient setting.
Exclusion Criteria:
- Type 1 diabetes
- Current participation in a clinical trial
- Presence of any condition/circumstance which in the opinion of the investigator could significantly limit the follow up of the patient (e.g. tourist, non-native speaker or does not understand the local language, psychiatric disturbances).
- Presence of serious/severe co-morbidities in the opinion of the investigator, which may limit treatment approach as usual.
- Treatment with drugs affecting glucose homeostasis (e.g., systemic glucocorticosteroids) within 3 months before to the 1st Visit
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Demographic parameters before dapagliflozin initiation in T2DM patients managed by GPs
기간: 3 months before dapagliflozin initiation
|
mean age
|
3 months before dapagliflozin initiation
|
|
demographic characteristics of T2DM patients managed by GPs
기간: 3 months before dapagliflozin initiation
|
age distribution
|
3 months before dapagliflozin initiation
|
|
demographic characteristics of T2DM patients managed by GPs
기간: 3 months before dapagliflozin initiation
|
gender distribution
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
기간: 3 months before dapagliflozin initiation
|
mean duration of T2DM
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
기간: 3 months before dapagliflozin initiation
|
HbA1c (mean and distribution)
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
기간: 3 months before dapagliflozin initiation
|
Weight (mean)
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
기간: 3 months before dapagliflozin initiation
|
SBP (mean and distribution)
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
기간: 3 months before dapagliflozin initiation
|
DBP (mean and distribution)
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
기간: 3 months before dapagliflozin initiation
|
Proportion of T2DM patients with diabetic complications
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
기간: 3 months before dapagliflozin initiation
|
Proportion of patients with T2DM treatment intensification during 3 months before inclusion in the study
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
기간: 3 months before dapagliflozin initiation
|
Proportion of patients with different treatment regimen
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
기간: 3 months before dapagliflozin initiation
|
Proportion of patients on treatment with different classes of antidiabetic therapy
|
3 months before dapagliflozin initiation
|
|
clinical characteristics of T2DM patients managed by GPs
기간: 3 months before dapagliflozin initiation
|
Proportion of patients on different classes of concomitant therapy
|
3 months before dapagliflozin initiation
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Vladimir Bulatov, MD, PhD, AstraZeneca Russia
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
제2형 당뇨병에 대한 임상 시험
-
Postgraduate Institute of Medical Education and...완전한
-
Hangzhou SynRx Therapeutics Biomedical Technology...모병유방암 | 난소 암 | 고급 고형 종양 | 전이성 고형 종양 | BRCA 1/2 및/또는 HRD중국